Primary ovarian cancer after colorectal cancer: a Dutch nationwide population-based study.
Colorectal cancer
Ovarian cancer
SIR
Journal
International journal of colorectal disease
ISSN: 1432-1262
Titre abrégé: Int J Colorectal Dis
Pays: Germany
ID NLM: 8607899
Informations de publication
Date de publication:
Jul 2022
Jul 2022
Historique:
accepted:
14
05
2022
pubmed:
14
6
2022
medline:
12
7
2022
entrez:
13
6
2022
Statut:
ppublish
Résumé
Women with colorectal cancer (CRC) are at risk not only of developing ovarian metastases, but also of developing a primary ovarian malignancy. Several earlier studies have in fact shown a link between the development of primary ovarian cancer and CRC. The purpose of this study was therefore to determine the risk of developing a primary ovarian cancer in women with prior CRC compared to the general population. Data from the Netherlands Cancer Registry were used. All women diagnosed with invasive CRC between 1989 and 2017 were included. Standardized incidence ratios (SIRs) and absolute excess risks (AERs) per 10,000 person-years were calculated. During the study period, 410 (0.3%) CRC patients were diagnosed with primary ovarian cancer. Women with CRC had a 20% increased risk of developing ovarian cancer compared to the general population (SIR = 1.2, 95% CI: 1.1-1.3). The AER of ovarian cancer was 0.9 per 10,000 person-years. The risk was especially increased within the first year of a CRC diagnosis (SIR = 3.3, 95% CI: 2.8-3.8) and in women aged ≤ 55 years (SIR = 2.0, 95% CI: 1.6-2.6). This study found a slightly increased risk of primary ovarian cancer in women diagnosed with CRC compared to the general population. However, this may be partly attributable to surveillance or detection bias. Nevertheless, our findings could be helpful for patient counseling, as CRC patients do not currently receive information concerning the increased risk of ovarian cancer.
Sections du résumé
BACKGROUND AND PURPOSE
OBJECTIVE
Women with colorectal cancer (CRC) are at risk not only of developing ovarian metastases, but also of developing a primary ovarian malignancy. Several earlier studies have in fact shown a link between the development of primary ovarian cancer and CRC. The purpose of this study was therefore to determine the risk of developing a primary ovarian cancer in women with prior CRC compared to the general population.
METHODS
METHODS
Data from the Netherlands Cancer Registry were used. All women diagnosed with invasive CRC between 1989 and 2017 were included. Standardized incidence ratios (SIRs) and absolute excess risks (AERs) per 10,000 person-years were calculated.
RESULTS
RESULTS
During the study period, 410 (0.3%) CRC patients were diagnosed with primary ovarian cancer. Women with CRC had a 20% increased risk of developing ovarian cancer compared to the general population (SIR = 1.2, 95% CI: 1.1-1.3). The AER of ovarian cancer was 0.9 per 10,000 person-years. The risk was especially increased within the first year of a CRC diagnosis (SIR = 3.3, 95% CI: 2.8-3.8) and in women aged ≤ 55 years (SIR = 2.0, 95% CI: 1.6-2.6).
CONCLUSION
CONCLUSIONS
This study found a slightly increased risk of primary ovarian cancer in women diagnosed with CRC compared to the general population. However, this may be partly attributable to surveillance or detection bias. Nevertheless, our findings could be helpful for patient counseling, as CRC patients do not currently receive information concerning the increased risk of ovarian cancer.
Identifiants
pubmed: 35697933
doi: 10.1007/s00384-022-04184-w
pii: 10.1007/s00384-022-04184-w
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1593-1599Informations de copyright
© 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
Références
Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68:394–424
doi: 10.3322/caac.21492
Pitt J, Dawson PM (1999) Oophorectomy in women with colorectal cancer. Eur J Surg Oncol 25:432–438
doi: 10.1053/ejso.1999.0671
Shin DW, Choi YJ, Kim HS, Han KD, Yoon H, Park YS, Kim N, Lee DH (2018) Secondary breast, ovarian, and uterine cancers after colorectal cancer: a nationwide population-based cohort study in Korea. Dis Colon Rectum 61:1250–1257
doi: 10.1097/DCR.0000000000001203
McCredie M, Macfarlane GJ, Bell J, Coates M (1997) Second primary cancers after cancers of the colon and rectum in New South Wales, Australia, 1972–1991. Cancer Epidemiol Biomarkers Prev 6:155–160
pubmed: 9138657
Berrington de Gonzalez A, Curtis RE, Kry SF, Gilbert E, Lamart S, Berg CD, Stovall M, Ron E (2011) The proportion of second cancers attributable to radiotherapy treatment in adults: a prospective cohort study in the US SEER cancer registries. Lancet Oncol 12:353–360
doi: 10.1016/S1470-2045(11)70061-4
Birgisson H, Påhlman L, Gunnarsson U, Glimelius B (2005) Occurrence of second cancers in patients treated with radiotherapy for rectal cancer. J Clin Oncol 23:6126–6131
doi: 10.1200/JCO.2005.02.543
Jia H, Li Q, Yuan J, Sun X, Wu Z (2020) Second primary malignancies in patients with colorectal cancer: a population-based analysis. Oncologist. https://doi.org/10.1634/theoncologist.2019-0266
doi: 10.1634/theoncologist.2019-0266
pubmed: 32864805
pmcid: 8108049
Bian X, Xia J, Wang K, Wang Q, Yang L, Wu W, Li L (2020) The effects of a prior malignancy on the survival of patients with ovarian cancer: a population-based study. J Cancer 11:6178–6187
doi: 10.7150/jca.46584
Hanna NN, Cohen AM (2004) Ovarian neoplasms in patients with colorectal cancer: understanding the role of prophylactic oophorectomy. Clin Colorectal Cancer 3:215–222
doi: 10.3816/CCC.2004.n.002
Banerjee S, Kapur S, Moran BJ (2005) The role of prophylactic oophorectomy in women undergoing surgery for colorectal cancer. Color Dis 7:214–217
doi: 10.1111/j.1463-1318.2005.00770.x
Paramythiotis D, Goulas P, Moysidis M, Karakatsanis A, Tzioufa-Asimakopoulou V, Sotiriou S, Michalopoulos A (2019) Metachronous ovarian metastases in a patient with primary colorectal cancer. A case report and review of the literature. Am J Case Rep 20:1515–1520
doi: 10.12659/AJCR.917957
Mayo Clinic [online]. https://www.mayoclinic.org/diseases-conditions/menopause/symptoms-causes/syc-20353397 . (Accessed 12 Dec 2021)
Zhang X, Liu L, Song F, Song Y, Dai H (2019) Ages at menarche and menopause, and mortality among postmenopausal women. Maturitas 130:50–56
doi: 10.1016/j.maturitas.2019.10.009
Roman Lay AA, do Nascimento CF, Horta BL, Dias Porto Chiavegatto Filho A (2020) Reproductive factors and age at natural menopause: a systematic review and meta-analysis. Maturitas 131:57–64
Ossewaarde ME, Bots ML, Verbeek ALM, Peeters PHM, Van Der Graaf Y, Grobbee DE, Van Der Schouw YT (2005) Age at menopause, cause-specific mortality and total life expectancy. Epidemiology 16:556–562
doi: 10.1097/01.ede.0000165392.35273.d4
Hemminki K, Li X, Dong C (2001) Second primary cancers after sporadic and familial colorectal cancer. Cancer Epidemiol Biomarkers Prev 10:793–798
pubmed: 11440965
Evans HS, Møller H, Robinson D, Lewis CM, Bell CMJ, Hodgson SV (2002) The risk of subsequent primary cancers after colorectal cancer in southeast England. Gut 50:647–652
doi: 10.1136/gut.50.5.647
Liang YH, Shao YY, Chen HM, Lai CL, Lin ZZ, Kuo RNC, Cheng AL, Yeh KH, Lai MS (2015) Young patients with colorectal cancer have increased risk of second primary cancers. Jpn J Clin Oncol 45:1029–1035
doi: 10.1093/jjco/hyv137
Lee YT, Liu CJ, Hu YW, Teng CJ, Tzeng CH, Yeh CM, Chen TJ, Lin JK, Lin CC, Lan YT, Wang HS, Yang SH, Jiang JK, Chen WS, Lin TC, Chang SC, Chen MH, Teng HW, Liu JH, Yen CC (2015) Incidence of second primary malignancies following colorectal cancer. Medicine (Baltimore) 94:7–11
Ahmed F, Goodman MT, Kosary C, Ruiz B, Wu X-C, Chen VW, Correa CN (2006) Excess risk of subsequent primary cancers among colorectal carcinoma survivors, 1975–2001. Cancer 107:1162–1171
doi: 10.1002/cncr.22013
Phipps AI, Chan AT, Ogino S (2013) Anatomic subsite of primary colorectal cancer and subsequent risk and distribution of second cancers. Cancer 119:3140–3147
doi: 10.1002/cncr.28076
Guan X, Jin Y, Chen Y, Jiang Z, Liu Z, Zhao Z, Yan P, Wang G, Wang X (2015) The incidence characteristics of second primary malignancy after diagnosis of primary colon and rectal cancer: a population based study. PLoS ONE 10:1–18
Yang L, Li S, Lv M, Wu Y, Chen Z, Shen Y, Wang B, Chen L, Yi M, Yang J (2017) Risk of subsequent primary malignancies among patients with prior colorectal cancer: a population-based cohort study. Onco Targets Ther 10:1535–1548
doi: 10.2147/OTT.S129220
Woodward ER, Sleightholme HV, Considine AM, Williamson S, McHugo JM, Cruger DG (2007) Annual surveillance by CA125 and transvaginal ultrasound for ovarian cancer in both high-risk and population risk women is ineffective. BJOG An Int J Obstet Gynaecol 114:1500–1509
doi: 10.1111/j.1471-0528.2007.01499.x
Yun HR, Yi LJ, Cho YK, Park JH, Cho YB, Yun SH, Kim HC, Chun HK, Lee WY (2009) Double primary malignancy in colorectal cancer patients - MSI is the useful marker for predicting double primary tumors. Int J Colorectal Dis 24:369–375
doi: 10.1007/s00384-008-0541-x
Overman MJ, Ernstoff MS, Morse MA (2018) Where we stand with immunotherapy in colorectal cancer: deficient mismatch repair, proficient mismatch repair, and toxicity management
Moreira L, Balaguer F, Lindor N, De La Chapelle A, Hampel H, Aaltonen LA, Hopper JL, Le Marchand L, Gallinger S, Newcomb PA, Haile R, Thibodeau SN, Gunawardena S, Jenkins MA, Buchanan DD, Potter JD, Baron JA, Ahnen DJ, Moreno V, Andreu M, De Leon MP, Rustgi AK, Castells A (2012) Identification of Lynch syndrome among patients with colorectal cancer. JAMA - J Am Med Assoc 308:1555–1565
doi: 10.1001/jama.2012.13088
Torre LA, Trabert B, DeSantis CE, Miller KD, Samimi G, Runowicz CD, Gaudet MM, Jemal A, Siegel RL (2018) Ovarian cancer statistics, 2018. CA Cancer J Clin 68:284–296
doi: 10.3322/caac.21456
Win AK, Hall MJ, Neumann CC (2020) Lynch syndrome (hereditary nonpolyposis colorectal cancer): clinical manifestations and diagnosis. https://www.uptodate.com/contents/lynch-syndrome-hereditary-nonpolyposis-colorectal-cancer-clinical-manifestations-and-diagnosis
Bucksch K, Zachariae S, Aretz S, Büttner R, Holinski-Feder E, Holzapfel S, Hüneburg R, Kloor M, Von Knebel Doeberitz M, Morak M, Möslein G, Nattermann J, Perne C, Rahner N, Schmiegel W, Schulmann K, Steinke-Lange V, Strassburg CP, Vangala DB, Weitz J, Loeffler M, Engel C (2020) Cancer risks in Lynch syndrome, Lynch-like syndrome, and familial colorectal cancer type X: A prospective cohort study. BMC Cancer 20:1–11
doi: 10.1186/s12885-020-06926-x
Bakkers C, van der Meer R, Roumen R, Lurvink RJ, Lemmens VE, van Erning FN, de Hingh IH (2020) Incidence, risk factors, treatment, and survival of ovarian metastases of colorectal origin : a Dutch population-based study. Int J Color Dis. https://doi.org/10.1007/s00384-020-03555-5
doi: 10.1007/s00384-020-03555-5
Segelman J, Floter-Radestad A, Hellborg H, Sjovall A, Martling A (2010) Epidemiology and prognosis of ovarian metastases in colorectal cancer. Br J Surg 97:1704–1709
doi: 10.1002/bjs.7196
Santandrea G, Piana S, Valli R, Zanelli M, Gasparini E, de Leo A, Mandato VD, Palicelli A (2021) Immunohistochemical biomarkers as a surrogate of molecular analysis in ovarian carcinomas: a review of the literature. Diagnostics. https://doi.org/10.3390/diagnostics11020199
doi: 10.3390/diagnostics11020199
pubmed: 34943486
pmcid: 8700750
Kim WY, Kim TJ, Kim SE, Lee JW, Lee JH, Kim BG, Bae DS (2010) The role of cytoreductive surgery for non-genital tract metastatic tumors to the ovaries. Eur J Obstet Gynecol Reprod Biol 149:97–101
doi: 10.1016/j.ejogrb.2009.11.011
Jiang R, Tang J, Cheng X, Zang RY (2008) Surgical treatment for patients with different origins of Krukenberg tumors : outcomes and prognostic factors *. Eur J Surg Oncol 35:92–97
doi: 10.1016/j.ejso.2008.05.006
Paschke S, Jafarov S, Staib L, Kreuser ED, Maulbecker-Armstrong C, Roitman M, Holm T, Harris CC, Link KH, Kornmann M (2018) Are colon and rectal cancer two different tumor entities? A proposal to abandon the term colorectal cancer. Int J Mol Sci 19:1–24
doi: 10.3390/ijms19092577
Lehrer S, Green S, Rosenzweig KE (2016) Reduced ovarian cancer incidence in women exposed to low dose ionizing background radiation or radiation to the ovaries after treatment for breast cancer or rectosigmoid cancer. Asian Pac J Cancer Prev 17:2979–2982
pubmed: 27356721
Csaba G (2018) Hormesis and immunity: a review. Acta Microbiol Immunol Hung 66:155–168
doi: 10.1556/030.65.2018.036